Cidara Therapeutics To Present Ongoing Development Of Drug-Fc Conjugates Including CD73-Targeting DFC From Its Cloudbreak Platform At Adenosine-Pathway Targeted Cancer Immunotherapy Summit Held June 20-22, 2023
Portfolio Pulse from Happy Mohamed
Cidara Therapeutics will present preclinical data on its CD73-targeting drug-Fc conjugate (DFC) CD421 and Cloudbreak platform at the Adenosine-Pathway Targeted Cancer Immunotherapy Summit. The company believes CD421 can serve as a beneficial alternative treatment option for cancer patients.
June 20, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cidara Therapeutics will present preclinical data on its CD73-targeting drug-Fc conjugate CD421 and Cloudbreak platform at the Adenosine-Pathway Targeted Cancer Immunotherapy Summit.
The presentation of preclinical data on CD421 and the Cloudbreak platform at the summit will likely generate interest in Cidara Therapeutics' ongoing research and development efforts. This could potentially lead to increased investor confidence and a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100